Can Namenda (memantine) cause brain fog, and how should it be managed?

Namenda Can Cause Confusion and Cognitive Side Effects Including Brain Fog

Yes, Namenda (memantine) can cause brain fog-like symptoms, specifically listed as "confusion" in its FDA-approved labeling, and should be discontinued if these symptoms become intolerable. 1, 2

Evidence from FDA Drug Label

The FDA label for Namenda explicitly lists confusion as a recognized adverse event occurring in 6% of patients (compared to 5% on placebo), along with dizziness (7%), headache (6%), and somnolence (3%) 2. These symptoms collectively can manifest as what patients describe as "brain fog"—a subjective experience of mental cloudiness, difficulty concentrating, and reduced cognitive clarity.

When to Discontinue Memantine for Cognitive Side Effects

The 2020 Canadian Consensus Conference on Dementia provides clear guidance on when memantine should be stopped due to intolerable side effects 1:

Discontinue memantine if:

• Development of intolerable side effects occurs, specifically listing confusion, dizziness, and falls as key concerns
• The cognitive side effects impair quality of life or safety
• Medication adherence becomes poor due to these symptoms

Management Algorithm

Step 1: Confirm the symptom is medication-related

• Assess timing: Did confusion/brain fog begin or worsen after starting memantine or dose escalation?
• Rule out other causes: delirium, concurrent illness, environmental changes, or other medications

Step 2: Evaluate severity and impact

• If symptoms are mild and tolerable: Consider dose reduction by 50% and monitor for 4 weeks 1
• If symptoms are moderate to severe or affecting safety/quality of life: Discontinue immediately

Step 3: Gradual discontinuation protocol 1

• Reduce dose by 50% every 4 weeks until reaching the initial starting dose
• After 4 weeks at starting dose, discontinue completely
• Monitor for worsening of dementia symptoms during taper

Step 4: Post-discontinuation monitoring

• Reinitiate treatment only if there is clinically meaningful worsening of cognition, function, or neuropsychiatric symptoms clearly related to cessation 1

Important Clinical Nuances

Paradoxical Cognitive Worsening

While memantine is intended to improve cognition in dementia, it can paradoxically worsen cognitive function in some patients. A 2009 study in multiple sclerosis patients found that memantine at 30 mg/day caused reversible neurologic impairment including blurred vision, severe headache, and walking difficulties, which resolved within days of stopping the medication 3. Though this was in MS patients, it demonstrates memantine's potential to cause acute cognitive and neurologic deterioration.

Dose-Dependent Effects

The adverse cognitive effects appear dose-dependent. The MS study noted symptoms only occurred at maximum dose (30 mg/day) 3. For dementia patients on the standard 20 mg/day dose experiencing brain fog, dose reduction is a reasonable first step before complete discontinuation.

Combination Therapy Concerns

If the patient is taking memantine with a cholinesterase inhibitor (donepezil, rivastigmine, galantamine), be aware that animal studies suggest donepezil may markedly potentiate memantine neurotoxicity 4. While this finding is from preclinical research, consider whether combination therapy might be contributing to cognitive side effects.

Risk-Benefit Reassessment

Remember that memantine's benefits are modest at best—the 2008 systematic review found only "statistically significant but clinically marginal improvement" in cognition 5. A 2013 meta-analysis confirmed memantine increases risk for confusion, somnolence, and nervous system disorders 6. If a patient experiences brain fog on memantine, the minimal benefit rarely justifies continuing the medication.

Common Pitfalls to Avoid

1. Don't attribute all cognitive changes to underlying dementia progression: New or worsening confusion after starting memantine should prompt consideration of medication-related effects, not just disease progression

2. Don't continue ineffective or harmful medication: The 2020 guidelines are clear that memantine should be stopped if no clinically meaningful benefit was observed or if intolerable side effects develop 1

3. Don't abruptly discontinue: Always taper gradually to avoid potential rebound worsening of dementia symptoms 1

4. Don't restart without clear indication: Only reinitiate if there is definitive clinical worsening attributable to cessation 1